---
reference_id: "PMID:37021532"
title: Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia.
authors:
- Lasaga M
- Río P
- Vilas-Zornoza A
- Planell N
- Navarro S
- Alignani D
- Fernández-Varas B
- Mouzo D
- Zubicaray J
- Pujol RM
- Nicoletti E
- Schwartz JD
- Sevilla J
- Ainciburi M
- Ullate-Agote A
- Surrallés J
- Perona R
- Sastre L
- Prosper F
- Gomez-Cabrero D
- Bueren JA
journal: Haematologica
year: '2023'
doi: 10.3324/haematol.2022.282418
content_type: abstract_only
---

# Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia.
**Authors:** Lasaga M, Río P, Vilas-Zornoza A, Planell N, Navarro S, Alignani D, Fernández-Varas B, Mouzo D, Zubicaray J, Pujol RM, Nicoletti E, Schwartz JD, Sevilla J, Ainciburi M, Ullate-Agote A, Surrallés J, Perona R, Sastre L, Prosper F, Gomez-Cabrero D, Bueren JA
**Journal:** Haematologica (2023)
**DOI:** [10.3324/haematol.2022.282418](https://doi.org/10.3324/haematol.2022.282418)

## Content

1. Haematologica. 2023 Oct 1;108(10):2652-2663. doi:
10.3324/haematol.2022.282418.

Gene therapy restores the transcriptional program of hematopoietic stem cells in 
Fanconi anemia.

Lasaga M(1), Río P(2), Vilas-Zornoza A(3), Planell N(1), Navarro S(2), Alignani 
D(4), Fernández-Varas B(5), Mouzo D(1), Zubicaray J(6), Pujol RM(7), Nicoletti 
E(8), Schwartz JD(8), Sevilla J(9), Ainciburi M(3), Ullate-Agote A(3), Surrallés 
J(7), Perona R(10), Sastre L(5), Prosper F(11), Gomez-Cabrero D(12), Bueren 
JA(13).

Author information:
(1)Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de 
Navarra (UPNA), IdiSNA, Pamplona, Spain.
(2)Hematopoietic Innovative Therapies Division, Centro de Investigaciones 
Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain; Centro de 
Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain; 
Instituto de Investigaciones Sanitarias. Fundación Jiménez Díaz, Madrid, Spain.
(3)Area de Hemato-Oncología, Centro de Investigación Médica Aplicada (CIMA), and 
Servicio de Hematologia y Terapia Celular, Clínica Universidad de Navarra, 
IDISNA, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer, 
CIBERONC.
(4)Flow Cytometry Core, CIMA, Universidad de Navarra, Pamplona, Spain.
(5)Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 
Madrid, Spain; Instituto de Investigaciones Biomédicas Alberto Sols, CSIC/UAM.
(6)Hemoterapia y Hematología Pediátrica, Fundación para la Investigación 
Biomédica, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
(7)Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 
Madrid, Spain; Departmento de Genética y Microbiología, Universitat Autónoma de 
Barcelona, Barcelona, Spain; Fundación Instituto de Investigación del Hospital 
de la Santa Creu y Sant Pau, Barcelona, Spain.
(8)Rocket Pharmaceuticals Inc, New York, NY, USA.
(9)Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 
Madrid, Spain; Hemoterapia y Hematología Pediátrica, Fundación para la 
Investigación Biomédica, Hospital Infantil Universitario Niño Jesús, Madrid, 
Spain.
(10)Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 
Madrid, Spain; Instituto de Investigaciones Biomédicas Alberto Sols, CSIC/UAM; 
Instituto de Salud Carlos III, Madrid, Spain.
(11)Area de Hemato-Oncología, Centro de Investigación Médica Aplicada (CIMA), 
and Servicio de Hematologia y Terapia Celular, Clínica Universidad de Navarra, 
IDISNA, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer, 
CIBERONC. Email:fprosper@unav.es.
(12)Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública 
de Navarra (UPNA), IdiSNA, Pamplona, Spain; Biological and Environmental Science 
and Engineering Division, King Abdullah University of Science and Technology 
(KAUST), Thuwal, Saudi Arabia; Bioscience Program, King Abdullah University of 
Science and Technology (KAUST), Thuwal, Saudi Arabia. 
David.gomezcabrero@kaust.edu.sa.
(13)Hematopoietic Innovative Therapies Division, Centro de Investigaciones 
Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain; Centro de 
Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain; 
Instituto de Investigaciones Sanitarias. Fundación Jiménez Díaz, Madrid, Spain. 
juan.bueren@ciemat.es.

Comment in
    Haematologica. 2023 Oct 01;108(10):2566-2567. doi: 
10.3324/haematol.2023.283031.

Clinical trials have shown that lentiviral-mediated gene therapy can ameliorate 
bone marrow failure (BMF) in nonconditioned Fanconi anemia (FA) patients 
resulting from the proliferative advantage of corrected FA hematopoietic stem 
and progenitor cells (HSPC). However, it is not yet known if gene therapy can 
revert affected molecular pathways in diseased HSPC. Single-cell RNA sequencing 
was performed in chimeric populations of corrected and uncorrected HSPC 
co-existing in the BM of gene therapy-treated FA patients. Our study 
demonstrates that gene therapy reverts the transcriptional signature of FA HSPC, 
which then resemble the transcriptional program of healthy donor HSPC. This 
includes a down-regulated expression of TGF-β and p21, typically up-regulated in 
FA HSPC, and upregulation of DNA damage response and telomere maintenance 
pathways. Our results show for the first time the potential of gene therapy to 
rescue defects in the HSPC transcriptional program from patients with inherited 
diseases; in this case, in FA characterized by BMF and cancer predisposition.

DOI: 10.3324/haematol.2022.282418
PMCID: PMC10542844
PMID: 37021532 [Indexed for MEDLINE]